Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cerilliant
Citi
QuintilesIMS
McKesson
Fish and Richardson
Covington
Daiichi Sankyo
US Army
Cantor Fitzgerald

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203411

« Back to Dashboard
NDA 203411 describes NEVIRAPINE, which is a drug marketed by Aurobindo, Sandoz Inc, Aurobindo Pharma Ltd, Alvogen Malta, Apotex Inc, Mylan Pharms Inc, Prinston Inc, Cipla Ltd, Cipla, Mylan Labs, Tech Organized, Macleods Pharms Ltd, Micro Labs Ltd, Hetero Labs Ltd Iii, and Strides Pharma, and is included in twenty-two NDAs. It is available from seventeen suppliers. Additional details are available on the NEVIRAPINE profile page.

The generic ingredient in NEVIRAPINE is nevirapine. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the nevirapine profile page.

Summary for NDA: 203411

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 203411

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEVIRAPINE
nevirapine
TABLET, EXTENDED RELEASE;ORAL 203411 ANDA Sandoz Inc 0781-5893 0781-5893-05 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (0781-5893-05)
NEVIRAPINE
nevirapine
TABLET, EXTENDED RELEASE;ORAL 203411 ANDA Sandoz Inc 0781-5893 0781-5893-31 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0781-5893-31)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength400MG
Approval Date:Apr 3, 2014TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Colorcon
Covington
Johnson and Johnson
Citi
Argus Health
Federal Trade Commission
Cipla
Dow
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot